{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-004094","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2025-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.322908+00:00","generated_at":"2026-05-18T19:14:21.785452+00:00","sec_items":["1.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Arbutus reacquires Greater China rights to imdusiran from Qilu Pharma; launches HBV SAB","bullets":["Mutual termination of License Agreement with Qilu Pharmaceutical for imdusiran in Greater China; no payments and all rights revert to Arbutus.","Arbutus now holds global rights to imdusiran; reports 8 patients achieved functional cure in Phase 2a trials IM-PROVE I/II to date.","New Scientific Advisory Board formed with five HBV experts to advise on late-stage clinical development of cHBV pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-004094","json":"https://secwatch.observer/filing/0001171843-25-004094.json","markdown":"https://secwatch.observer/filing/0001171843-25-004094.md","text":"https://secwatch.observer/filing/0001171843-25-004094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325004094/0001171843-25-004094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325004094/f8k_062525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T19:14:21.785452+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}